Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data may reveal how well tafasitamab fights Hard-to-Treat lymphoma

NCT ID NCT07709624

Disease control Sponsor: TTY Biopharm Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study looks at how well the drug tafasitamab works in adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatment. Researchers will collect real-world data from 50 patients who are not eligible for a stem cell transplant. The main goal is to see how many patients achieve a complete or partial response to the drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tafasitamab
What this could lead to
If successful, this study could confirm tafasitamab's effectiveness in a broader, real-world population of DLBCL patients who cannot have a stem cell transplant.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection or other treatments. The small size (50 patients) limits how widely findings can be applied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

R/R DLBCL who are ineligible for ASCT

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients aged ≥18 years at the time of tafasitamab initiation. 2. Patients who were initiated on tafasitamab treatment between August 1, 2024, and December 31, 2028. 3. Patients with a histologically confirmed diagnosis of DLBCL. 4. Patients ineligible for ASCT based on clinical judgment, comorbidities, or other relevant factors. 5. Patients must have relapsed or refractory disease following at least one prior systemic regimen for DLBCL, with at least one line of therapy including a CD20-targeted agent (e.g., rituximab). Exclusion Criteria: 1\. Patients who are alive but unable or unwilling to provide written informed consent. \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DLBCL

Contacts and locations

Locations

  • Tty Biopharm

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.